Sutro Biopharma
Stock Forecast, Prediction & Price Target
Sutro Biopharma (STRO) stock Price Target by analysts
$12
Potential upside: 1293.72%
Sutro Biopharma price prediction
What is Sutro Biopharma stock analysts` prediction?
Sutro Biopharma stock forecast: Based on 2 Wall Street analysts` predicted price targets for Sutro Biopharma in the last 3 months, the avarage price target is $12, with a high forecast of $NaN. The average price target represents a 1293.72% change from the last price of $0.86.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Sutro Biopharma stock Price Target by analysts
Full breakdown of analysts given Sutro Biopharma price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Tazeen Ahmad Bank of America Securities | 0% 0/1 | 12 months ago | $12 1293.72% upside | $3.61 | StreetInsider | Previous targets (0) |
Andrew Fein H.C. Wainwright | 0% 0/1 | 12 months ago | $12 1293.72% upside | $3.61 | StreetInsider | Previous targets (0) |
Asthika Goonewardene Truist Financial | 0% 0/2 | about 1 year ago | $15 1642.16% upside | $4.21 | StreetInsider | Previous targets (1) |
James Shin Deutsche Bank | 0% 0/1 | over 1 year ago | $10 1061.44% upside | $4.34 | StreetInsider | Previous targets (0) |
David Nierengarten Wedbush | 0% 0/1 | over 1 year ago | $8 829.15% upside | $4.23 | StreetInsider | Previous targets (0) |
Edward Tenthoff Piper Sandler | 0% 0/2 | over 1 year ago | $11 1177.58% upside | $5.09 | StreetInsider | Previous targets (1) |
Jay Olson Oppenheimer | 0% 0/1 | over 1 year ago | $10 1061.44% upside | $5.09 | StreetInsider | Previous targets (0) |
Asthika Goonewardene Truist Financial | 0% 0/2 | over 1 year ago | $18 1990.59% upside | $5.09 | StreetInsider | Previous targets (1) |
Unknown Truist Financial | N/A | over 2 years ago | $25 2803.60% upside | $8.14 | Benzinga | N/A |
Unknown Piper Sandler | N/A | over 2 years ago | $18 1990.59% upside | $8.29 | Benzinga | N/A |
Edward Tenthoff Piper Sandler | 0% 0/2 | about 3 years ago | $16 1758.30% upside | $5.05 | TheFly | Previous targets (1) |
Sutro Biopharma Financial Estimates
Sutro Biopharma Revenue Estimates
Sutro Biopharma EBITDA Estimates
Sutro Biopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $61.88M N/A | $67.77M 9.52% | $153.73M 126.83% | Avg: $62.17M Low: $16.76M High: $182.76M avg. -59.55% | Avg: $81.65M Low: $29.61M High: $207.36M avg. 31.33% | Avg: $147.10M Low: $53.36M High: $373.59M avg. 80.16% | Avg: $319.24M Low: $115.80M High: $810.73M avg. 117.00% |
Net Income
% change YoY
| $-108.67M N/A | $-119.20M -9.68% | $-106.79M 10.41% | Avg: $-270.76M Low: $-292.39M High: $-44.52M avg. -153.54% | Avg: $-269.37M Low: $-285.77M High: $-58.35M avg. 0.51% | Avg: $-143.86M Low: $-431.80M High: $-24.68M avg. 46.59% | Avg: $-65.73M Low: $-197.29M High: $-11.27M avg. 54.30% |
EBITDA
% change YoY
| $-93.10M N/A | $-125.48M -34.78% | $-67.91M 45.87% | Avg: $-56.40M Low: $-165.81M High: $-15.20M avg. 16.94% | Avg: $-74.08M Low: $-188.13M High: $-26.87M avg. -31.33% | Avg: $-133.46M Low: $-338.95M High: $-48.41M avg. -80.16% | Avg: $-289.64M Low: $-735.56M High: $-105.06M avg. -117.00% |
EPS
% change YoY
| -$2.36 N/A | -$2.35 0.42% | -$1.78 24.25% | Avg: -$3.24 Low: -$4.86 High: -$0.74 avg. -81.93% | Avg: -$2.99 Low: -$4.75 High: -$0.97 avg. 7.55% | Avg: -$2.39 Low: -$7.18 High: -$0.41 avg. 20.12% | Avg: -$1.09 Low: -$3.28 High: -$0.19 avg. 54.30% |
Operating Expenses
% change YoY
| $160.40M N/A | $196.71M 22.63% | $243.00M 23.53% | Avg: $46.88M Low: $12.64M High: $137.83M avg. -80.70% | Avg: $61.58M Low: $22.33M High: $156.38M avg. 31.33% | Avg: $110.94M Low: $40.24M High: $281.75M avg. 80.16% | Avg: $240.76M Low: $87.33M High: $611.42M avg. 117.00% |
FAQ
What is Sutro Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -13.03% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -292.39M, average is -270.76M and high is -44.52M.
What is Sutro Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 42.23% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is $16.76M, average is $62.17M and high is $182.76M.
What is Sutro Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 0.01% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$4.86, average is -$3.24 and high is $-0.74.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Sutro Biopharma stock. The most successful analyst is Tazeen Ahmad.